Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + everolimus
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination involves **paclitaxel**, a microtubule inhibitor used in chemotherapy, and **everolimus**, an mTOR inhibitor used in cancer treatment and as an immunosuppressant. Paclitaxel works by stabilizing microtubules, preventing cell division, while everolimus inhibits the mammalian target of rapamycin (mTOR), affecting cell growth and proliferation.
- Brand names
- TaxolAbraxaneAfinitorCertican
- Other names
- paclitaxel + RAD001paclitaxel + everolimus
02
Targets
TUBB (Tubulin (alpha and beta subunits))Mechanistic target of rapamycin complex 1FKBP1A
Beyond the preview
Go deeper on paclitaxel + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + everolimus.